Pushing biology to regain neurological function

NeuroHeal Biomedicals is focused on the development of a first-in-class agent to improve recovery of function after peripheral nerve damage

Peripheral nerves sustain our living activities; to move, to walk, to jump, to catch, to hold, to hug, to feel…

Numbness, pain, and tingling are feelings related to peripheral neuropathy, and accounts for sensory, motor or autonomic dysfunction.

Peripheral neuropathy can be caused by traumatic injury, infections, metabolic problems, inherited causes and exposure to toxins.

Traumatic lesion, nerve crush, compression, entrapment or ischemia damage the peripheral nerves leading to devastating life-altering consequences. It affects to 1 per 1000 habitants per year, which is around 730,000 people/year in Europe to 1.2 Million persons in China per year, and usually on working age, what elevate considerable the socioeconomic cost.

Vision, Mission and Strategy

Vision

We are passionate about helping to regain neurological and neuromuscular function to patients, and ameliorate their quality of life by innovating effective treatments that push cells on the restoring process.

 Peripheral nerves have some intrinsic ability to regenerate after injury. However, several factors slow down the process, leading to muscle atrophy, and scarce functional recovery. Engaging neurons to push nerve regeneration accelerates the process and improves the regain of neurological functions.

Mission

Our mission is developing NeuroHeal to become the standard of care in the treatment after nervous and musculoskeletal system damage, currently without a specific cure.

The management of traumatic peripheral nerve is complex depending on several factors like the type, the location, and the time after injury, although commonly it includes surgery, the use of corticosteroids, analgesics, and later on, physical rehabilitation to achieve modest functional recovery. Currently, there is no co-adjuvant treatment to enhance recovery or to avoid the apparition of neuropathic pain representing an unmet medical need.

Mission

Our mission is developing NeuroHeal to become the standard of care in the treatment after nervous and musculoskeletal system damage, currently without a specific cure.

The management of traumatic peripheral nerve is complex depending on several factors like the type, the location, and the time after injury, although commonly it includes surgery, the use of corticosteroids, analgesics, and later on, physical rehabilitation to achieve modest functional recovery. Currently, there is no co-adjuvant treatment to enhance recovery or to avoid the apparition of neuropathic pain representing an unmet medical need.

Strategy

NeuroHeal Biomedicals vocation is building a robust portfolio addressing peripheral nerve damage and associated neuropathic pain through an innovative platform that combines systems biology approach for data mining, and the use of artificial intelligence-based computational tools for drug discovery.

The Product

NeuroHeal foster neuronal intrinsic capabilities for neuroprotection, nerve regeneration and reinnervation, improving and accelerating functional recovery after damage.

NeuroHeal is a patented product resulting from the synergistic action of two approved drugs: acamprosate and ribavirin.

An innovative platform for drug discovery

The combo was designed by an innovative drug-discovery workflow using:

  • Biological data from relevant preclinical models.
  • A systems biology approach for data meaning.
  • Artificial intelligence-based computational tools  to emulate the behavior of the human nervous system in silico.

Neuroheal can be administered orally to protect motor neurons, to reduce gliosis, to reduce muscle atrophy, and to accelerate nerve regeneration.

NeuroHeal accomplish these effects by turning out the whole molecular neural picture from a degenerative-mode to a regenerative-mode. NeuroHeal’s mechanism of action is mediated by the activation the NAD+-dependent deacetylase sirtuin-1 among other factors, which are required for cell homeostasis, neuroprotection and regeneration.

Our history

NeuroHeal Biomedicals S.L. is a biotechnological company, participated by the Universitat Autònoma de Barcelona, that was incorporated on October 3, 2019.

 

NeuroHeal, the first product in the pipeline, is still under development although first clinical assays are expected to start in 2022.

About us

Neuroheal Biomedicals was founded by Caty Casas, Ph.D., David Romeo, Ph.D., from the Universitat Autònoma de Barcelona, and Joaquim Forés M.D., Ph.D., from Hospital Clínic de Barcelona. Josep Lluis Falcó, Ph.D., director of GENESIS Biomed is the Chief Executive Officer, responsible for the strategic direction and business development of the company.

Caty Casas Louzao, PhD

Co-founder

Joaquim Forés, M.D

Co-founder 

David Romeo, PhD

Co-founder

Josep LLuis Falcó, PhD

 

Caty Casas, Ph.D. in Biology from the Universitat de Barcelona is an associate professor at the Universitat Autònoma de Barcelona (UAB) and she is a principal investigator in the Neuroplasticity and Regeneration Group of the Institute of Neuroscience at UAB. She has a multidisciplinary formation with a Ph.D. in human molecular genetics in the laboratory of Professor Xavier Estivill, and a Marie-Curie granted postdoctoral research and biotech experience on neurodegenerative diseases at the Centre de Recherche of Sanofi-Aventis in Paris where she presented her first patent. Dr Casas has more than 15 years of outstanding research experience in the field of neurodegenerative processes of motoneurons after traumatic injury with more than 43 peer-reviewed scientific articles, some in high-impact journals and many as corresponding author, with more than 4000 citations, and a total of 6 submitted biomedical patents, half of them licensed. She has been participated in 23 funded Projects, 8 of them as principal investigator, from several national and international agencies, attracting more than one million euros. She was the founder and Chaired of an international network devoted to the translation of knowledge in the autophagy field called TRANSAUTOPHAGY encompassing with more than 300 researches from 30 European and neighbor countries and granted with an H2020-COST Action funding. She is member of SEFAGIA and founder member of a recently granted Spanish Network on Systems Neuroscience. She has received formation in entrepreneurship at the Cambridge University, UK (Cambridge Ignite program), and at the Toulouse Business School in Barcelona.

Joaquim Forés is M.D. (1987), Ph.D. (1992) from UAB, is working as a Senior Consultant at the Orthopedic and Traumatology Unit of the Hospital Clinic de Barcelona, and Vice-Chair of the medical ethic committee at the same Institution. He has been long-term collaborator within the group of Neuroplasticity and Regeneration at the Institut de Neurociències at the UAB with an outstanding contribution in setting-up animal models with microsurgery. He is committed as assessor in clinical issues of the Project. He has participated in more than 61 publications and 4 book chapters, in 25 granted projects, 5 of them as principal investigator, and received an award of investigation (American Society for Surgery of the Hand, 2013). He is also associated professor at the Faculty of Medicine from the Universitat de Barcelona and Bon Samaritaine (Txad, 2012-2018).

David Romeo has a Ph.D. (2017) in Neuroscience from UAB working in the discovery of NeuroHeal within Dr Casas team lab. He investigated the potential of the use of Systems biology approaches and Artificial Neuronal Networks to obtain novel and effective therapies for nerve injuries. He is currently an early-career postdoctoral researcher at the Dr. Franck Oury’s lab at the INSERM in the Institut Necker Enfants-Malades (INEM), in Paris (France). He has published 6 peer-review articles and presented his research in several international and national scientific congresses. He has submitted two patents and participated in courses for entrepeneurship (Generalitat de Catalunya).

Josep Lluís Falcó, Ph.D. from Institut Químic de Sarrià (IQS) and is founder and CEO of Genesis BioMed and Genesis Venture. He has 20 years of experience in the biomedical sector. His experience is based in Healthcare Strategy, Technology Transfer, Fundraising of start-up companies, Business Development, Marketing, Market Access, Reimbursement and Regulatory Affairs. He has worked for big pharma companies (Sanofi), mid-size pharmas (Ferrer Grupo), small biotechs (Hospital spin-off), Tech Transfer Offices (Fundació Bosch i Gimpera) and consulting firms (Antares Consulting and Asphalion). He has also been associate professor at IQS. In the last 4 years, he has been involved in 6 private fundraising processes and he has contributed to raise 33.5 million euros for his clients.

NeuroHeal Biomedicals: a new technology-based company of the UAB to develop a new treatment for peripheral nerve damage

NeuroHeal Biomedicals: a new technology-based company of the UAB to develop a new treatment for peripheral nerve damage  NeuroHeal Biomedicals will advance the development of a new drug to restore peripheral nerve well function. The objective of the company is to...

NeuroHeal Biomedicals: una nueva empresa de base tecnológica de la UAB para desarrollar un nuevo tratamiento para lesiones nerviosas

NeuroHeal Biomedicals, impulsada por un equipo investigador del INc-UAB, avanzará en el desarrollo de un nuevo medicamento que neuroprotege y acelera la regeneración nerviosa y la recuperación funcional después de lesiones del nervio periférico. El objetivo de la...

NeuroHeal Biomedicals: una nova empresa de base tecnològica de la UAB per desenvolupar un nou tractament per a lesions nervioses

NeuroHeal Biomedicals, impulsada per un equip investigador de l’INc-UAB, avançarà en el desenvolupament d’un nou medicament que neuroprotegeix i accelera la regeneració nerviosa i la recuperació funcional després de lesions de nervi perifèric.

Investors

Our main goal is to develop medication to improve painless recovery after peripheral nerve injury until its clinical use. Our partners are essentials to reach milestones. We are currently supported by:

Contact

Adress

Neuroheal Biomedicals, S.L.

EUREKA Building-Parc de Recerca-UAB

Av Can Domènech s/n

08193 Bellaterra

Barcelona